Why does cervical cancer occur in a state-of-the-art screening program?

Gynecologic Oncology

Volumn 146, Issue 3, 2017, Pages 546-553

  Castle, Philip E ^a   Kinney, Walter K ^b   Cheung, Li C ^c   Gage, Julia C ^c   Fetterman, Barbara ^b   Poitras, Nancy E ^b   Lorey, Thomas S ^b   Wentzensen, Nicolas ^c   Befano, Brian ^d   Schussler, John ^d   Katki, Hormuzd A ^c   Schiffman, Mark ^c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b KAISER PERMANENTE MEDICAL CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d IMS Inc   (United States)

Author keywords

Cervical cancer; CIN3; Cotesting; Cytology; Human papillomavirus (HPV); Precancer

Indexed keywords

ADENOSQUAMOUS CARCINOMA; ADULT; AMERICAN INDIAN; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CAUCASIAN; CLEAR CELL CARCINOMA; COHORT ANALYSIS; COLPOSCOPY; CONDYLOMA ACUMINATUM; DIAGNOSTIC VALUE; FALSE NEGATIVE RESULT; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PRECANCER; PRIORITY JOURNAL; SMALL CELL CARCINOMA; TREATMENT FAILURE; UTERINE CERVIX ADENOCARCINOMA; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS; ADENOCARCINOMA; AGE; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYTODIAGNOSIS; EARLY CANCER DIAGNOSIS; ISOLATION AND PURIFICATION; MIDDLE AGED; PAPILLOMAVIRIDAE; PATHOLOGY; PATIENT COMPLIANCE; PRECANCEROUS CONDITIONS; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ADENOCARCINOMA; ADULT; AGE FACTORS; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYTODIAGNOSIS; EARLY DETECTION OF CANCER; FALSE NEGATIVE REACTIONS; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PATIENT COMPLIANCE; PRECANCEROUS CONDITIONS; TREATMENT FAILURE; UTERINE CERVICAL NEOPLASMS;

EID: 85020434336     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2017.06.003     Document Type: Article

References (44)

1. Schiffman, M., Castle, P.E., Jeronimo, J., Rodriguez, A.C., Wacholder, S., Human papillomavirus and cervical cancer. Lancet 370 (2007), 890–907.
2. Ronco, G., Dillner, J., Elfstrom, K.M., Tunesi, S., Snijders, P.J., Arbyn, M., et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 383 (2014), 524–532.
3. Cuzick, J., Clavel, C., Petry, K.U., Meijer, C.J., Hoyer, H., Ratnam, S., et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer 119 (2006), 1095–1101.
4. Castle, P.E., de Sanjosé, S., Qiao, Y.L., Belinson, J.L., Lazcano-Ponce, E., Kinney, W., et al. Vaccine 30:Suppl. 5 (2012), F117–F122.
5. Wright, T.C. Jr., Schiffman, M., Solomon, D., Cox, J.T., Garcia, F., Goldie, S., et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet. Gynecol. 103 (2004), 304–309.
6. Kinney, W., Wright, T.C., Dinkelspiel, H.E., DeFrancesco, M., Thomas, C.J., Huh, W., Increased cervical cancer risk associated with screening at longer intervals. Obstet. Gynecol. 125 (2015), 311–315.
7. Felix, J.C., Lacey, M.J., Miller, J.D., Lenhart, G.M., Spitzer, M., Kulkarni, R., The clinical and economic benefits of co-testing versus primary HPV testing for cervical cancer screening: a modeling analysis. J. Women's Health (Larchmt) 25:6 (2016), 606–616.
8. Naber, S.K., De Kok, I.M., Matthijsse, S.M., van Ballegooijen, M., The potential harms of primary human papillomavirus screening in over-screened women: a microsimulation study. Cancer Causes Control 27 (2016), 569–581.
9. Davis, M., Feldman, S., Making sense of cervical cancer screening guidelines and recommendations. Curr. Treat. Options in Oncol. 16 (2015), 55–0373.
10. Wentzensen, N., Arbyn, M., HPV-based cervical cancer screening- facts, fiction, and misperceptions. Prev. Med. 98 (2017), 33–35, 10.1016/j.ypmed.2016.12.040 (Epub;%2017 Feb 6.:33-5).
11. http://www.uspreventiveservicestaskforce.org/Page/Document/draft-research-plan179/cervical-cancer-screening2. 5-28-2015. Ref type: internet communication.
12. Katki, H.A., Kinney, W.K., Fetterman, B., Lorey, T., Poitras, N.E., Cheung, L., et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 12 (2011), 663–672.
13. Gage, J.C., Schiffman, M., Katki, H.A., Castle, P.E., Fetterman, B., Wentzensen, N., et al. Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test. J. Natl. Cancer Inst., 106, 2014 (dju153).
14. Wright, T.C. Jr., Cox, J.T., Massad, L.S., Twiggs, L.B., Wilkinson, E.J., 2001 consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 287 (2002), 2120–2129.
15. Wright, T.C. Jr., Massad, L.S., Dunton, C.J., Spitzer, M., Wilkinson, E.J., Solomon, D., 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. J. Low. Genit. Tract Dis. 11 (2007), 223–239.
16. Wright, T.C. Jr., Massad, L.S., Dunton, C.J., Spitzer, M., Wilkinson, E.J., Solomon, D., 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J. Low. Genit. Tract Dis. 11 (2007), 201–222.
17. Massad, L.S., Einstein, M.H., Huh, W.K., Katki, H.A., Kinney, W.K., Schiffman, M., et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J. Low. Genit. Tract Dis. 17 (2013), S1–S27.
18. Wright, T.C. Jr., Massad, L.S., Dunton, C.J., Spitzer, M., Wilkinson, E.J., Solomon, D., 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am. J. Obstet. Gynecol. 197 (2007), 340–345.
19. Moscicki, A.B., Schiffman, M., Burchell, A., Albero, G., Giuliano, A.R., Goodman, M.T., et al. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine 30:Suppl. 5 (2012), F24–F33, 10.1016/j.vaccine.2012.05.089 (20).
20. Vink, M.A., Bogaards, J.A., van Kemenade, F.J., de Melker, H.E., Meijer, C.J., Berkhof, J., Clinical progression of high-grade cervical intraepithelial neoplasia: estimating the time to preclinical cervical cancer from doubly censored national registry data. Am. J. Epidemiol. 178 (2013), 1161–1169.
21. Plummer, M., Peto, J., Franceschi, S., Time since first sexual intercourse and the risk of cervical cancer. Int. J. Cancer 130 (2012), 2638–2644.
22. Santesso, N., Mustafa, R.A., Wiercioch, W., Kehar, R., Gandhi, S., Chen, Y., et al. Systematic reviews and meta-analyses of benefits and harms of cryotherapy, LEEP, and cold knife conization to treat cervical intraepithelial neoplasia. Int. J. Gynaecol. Obstet. 132 (2016), 266–271.
23. Cuzick, J., A Wilcoxon-type test for trend. Stat. Med. 4 (1985), 87–90.
24. McCredie, M.R., Sharples, K.J., Paul, C., Baranyai, J., Medley, G., Jones, R.W., et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 9 (2008), 425–434.
25. Integrated genomic and molecular characterization of cervical cancer. Nature, 543, 2017, 378–384.
26. Khan, M.J., Castle, P.E., Lorincz, A.T., Wacholder, S., Sherman, M., Scott, D.R., et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl. Cancer Inst. 20:97 (2005), 1072–1079.
27. Castle, P.E., Solomon, D., Schiffman, M., Wheeler, C.M., Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J. Natl. Cancer Inst. 20:97 (2005), 1066–1071.
28. Castle, P.E., Glass, A.G., Rush, B.B., Scott, D.R., Wentzensen, N., Gage, J.C., et al. Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up. J. Clin. Oncol. 30 (2012), 3044–3050.
29. Castle, P.E., Stoler, M.H., Wright, T.C. Jr., Sharma, A., Wright, T.L., Behrens, C.M., Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 12 (2011), 880–890.
30. Carozzi, F., Confortini, M., Palma, P.D., Del, M.A., Gillio-Tos, A., De, M.L., et al. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol. 9:10 (2008), 937–945.
31. Carozzi, F., Gillio-Tos, A., Confortini, M., Del, M.A., Sani, C., De, M.L., et al. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol. 14 (2013), 168–176.
32. Wentzensen, N., Fetterman, B., Castle, P.E., Schiffman, M., Wood, S.N., Stiemerling, E., et al. p16/Ki-67 dual stain cytology for detection of cervical precancer in HPV-positive women. J. Natl. Cancer Inst., 107, 2015 (djv257).
33. Bergeron, C., Giorgi-Rossi, P., Cas, F., Schiboni, M.L., Ghiringhello, B., Dalla, P.P., et al. Informed cytology for triaging HPV-positive women: substudy nested in the NTCC randomized controlled trial. J. Natl. Cancer Inst., 107, 2015 (dju423).
34. Sahasrabuddhe, V.V., Luhn, P., Wentzensen, N., Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts. Future Microbiol 6 (2011), 1083–1098.
35. Pretorius, R.G., Zhang, W.H., Belinson, J.L., Huang, M.N., Wu, L.Y., Zhang, X., et al. Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse. Am. J. Obstet. Gynecol. 191 (2004), 430–434.
36. Surveillance, Epidemiology, and End Results (SEER) Program ( www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2013 Sub (1973–2011) < Katrina/Rita Population Adjustment > - Linked To County Attributes - Total U.S., 1969–2012 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2014, based on the November 2013 submission. 2014. U.S. National Cancer Institute. 11-13-2014. Ref type: online source.
37. Castanon, A., Landy, R., Cuzick, J., Sasieni, P., Cervical screening at age 50–64 years and the risk of cervical cancer at age 65 years and older: population-based case control study. PLoS Med., 11, 2014, e1001585.
38. Sawaya, G.F., Kulasingam, S., Denberg, T.D., Qaseem, A., Cervical cancer screening in average-risk women: best practice advice from the Clinical Guidelines Committee of the American College of Physicians. Ann. Intern. Med. 162 (2015), 851–859.
39. Peirson, L., Fitzpatrick-Lewis, D., Ciliska, D., Warren, R., Screening for cervical cancer: a systematic review and meta-analysis. Syst. Rev., 2(35), 2013, 10.1186/2046-4053-2-35 (35-2).
40. White, M.C., Shoemaker, M.L., Benard, V.B., Cervical cancer screening and incidence by age: unmet needs near and after the stopping age for screening. Am. J. Prev. Med., 10, 2017.
41. Rositch, A.F., Nowak, R.G., Gravitt, P.E., Increased age and race-specific incidence of cervical cancer after correction for hysterectomy prevalence in the United States from 2000 to 2009. Cancer 120 (2014), 2032–2038.
42. Saslow, D., Solomon, D., Lawson, H.W., Killackey, M., Kulasingam, S.L., Cain, J., et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J. Clin. 62 (2012), 147–172.
43. Castle, P.E., Sideri, M., Jeronimo, J., Solomon, D., Schiffman, M., Risk assessment to guide the prevention of cervical cancer. J. Low. Genit. Tract Dis. 12 (2008), 1–7.
44. Silver, M.I., Schiffman, M., Fetterman, B., Poitras, N.E., Gage, J.C., Wentzensen, N., et al. The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals: reduced cervical cancer risk and decreased yield of precancer per screen. Cancer, 10, 2016.